NCT01635023View on ClinicalTrials.gov

A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Healthy Volunteers
Interventions
DRUG

AZD6244 Dosing Period 1

Treatment A, B, or C depending on randomization assignment

DRUG

AZD6244 Dosing Period 2

Treatment A, B, or C depending on randomization assignment

DRUG

AZD6244 Dosing Period 3

Treatment A, B, or C depending on randomization assignment

DRUG

AZD6244 Dosing Period 4

Treatment B

Trial Locations (1)

Unknown

Reseatch Site, Overland Park

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY